Whalesbook
Aptus Pharma Ltd. has announced its audited financial results for the fiscal year ending March 31, 2026, reporting revenue of ₹4,657.46 lakh (₹46.57 crore) and a profit after tax of ₹461.99 lakh (₹4.62 crore).
Alongside these results, the company's Board of Directors approved a 3:2 bonus share issue. This means shareholders will receive three new equity shares for every two shares they hold. The record date for determining eligibility for these bonus shares is set for May 12, 2026.
This announcement follows Aptus Pharma's successful Initial Public Offering (IPO) in September 2025. The Gujarat-based company operates primarily as a marketer and distributor of pharmaceutical formulations, utilizing an asset-light model through contract manufacturing. Its diverse product portfolio covers cardiac, diabetic, acute care, and nutraceutical segments.
While the statutory auditors issued an unmodified opinion on the full-year FY26 financial statements, their report highlighted specific concerns. These include uncertainty regarding the company's ability to continue as a going concern, which requires careful monitoring of management's plans. Additionally, the auditors noted a higher risk of material misstatements due to fraud compared to errors. The review of interim half-year financial figures was limited, indicating less scrutiny for these periods.
For the preceding fiscal year, FY25, Aptus Pharma reported revenue of ₹2,455.77 lakh (₹24.56 crore) and a profit after tax of ₹309.96 lakh (₹3.10 crore). This shows a significant year-on-year revenue increase of approximately 89.64% and a profit after tax growth of about 49.05% from FY25 to FY26.
Operating in the large Indian pharmaceutical sector, Aptus Pharma distinguishes itself with a smaller market capitalization, estimated around ₹250-260 crore. Unlike integrated manufacturers, its niche strategy focuses on specific therapeutic segments through its marketing and distribution network. Major players in the broader Indian pharmaceutical market include companies like Sun Pharmaceutical Industries, Divi's Laboratories, and Torrent Pharmaceuticals.
Looking ahead, investors should note the May 12 record date for the bonus shares. Key watchpoints include how Aptus Pharma addresses the going concern uncertainty and other auditor remarks in future communications. Performance in FY27 and any further corporate actions enabled by the company's expanded authorised share capital will also be important to monitor.